<table id="ID314" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Extended-Release Tablets</caption>
<col width="19%"></col>
<col width="81%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Inhibitors </content>
<content stylecode="bold">of </content>
<content stylecode="bold">CYP2D6</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent µ-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome.<br/>
<br/>After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase which could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, and may cause potentially fatal respiratory depression <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Pharmacology </content>
<content stylecode="italics">(</content>
<content stylecode="italics">12</content>
<content stylecode="italics">.</content>
<content stylecode="italics">3</content>)].<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">If concomitant use of a CYP2D6 inhibitor is necessary, follow patients closely for adverse reactions including opioid withdrawal, seizures, and serotonin syndrome.<br/>
<br/>If a CYP2D6 inhibitor is discontinued, consider lowering tramadol hydrochloride extended-release tablets dosage until stable drug effects are achieved. Follow patients closely for adverse events including respiratory depression and sedation.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Quinidine, fluoxetine, paroxetine and bupropion<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Inhibitors </content>
<content stylecode="bold">of </content>
<content stylecode="bold">CYP3A4</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The concomitant use of tramadol hydrochloride extended-release tablets and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Follow patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved.<br/>
<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Pharmacology </content>
<content stylecode="italics">(</content>
<content stylecode="italics">12</content>
<content stylecode="italics">.</content>
<content stylecode="italics">3</content>)], resulting in decreased opioid efficacy and possibly signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">If concomitant use is necessary, consider dosage reduction of tramadol hydrochloride extended-release tablets until stable drug effects are achieved. Follow patients closely for seizures and serotonin syndrome, and signs of respiratory depression and sedation at frequent intervals. If a CYP3A4 inhibitor is discontinued, consider increasing the tramadol hydrochloride extended-release tablets dosage until stable drug effects are achieved and follow patients for signs and symptoms of opioid withdrawal.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">CYP3A4 </content>
<content stylecode="bold">Inducers</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The concomitant use of tramadol hydrochloride extended-release tablets and CYP3A4 inducers can decrease the plasma concentration of tramadol <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Pharmacology </content>
<content stylecode="italics">(</content>
<content stylecode="italics">12</content>
<content stylecode="italics">.</content>
<content stylecode="italics">3</content>)], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol, <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Warnings </content>
<content stylecode="italics">and </content>
<content stylecode="italics">Precautions </content>
<content stylecode="italics">(</content>
<content stylecode="italics">5</content>
<content stylecode="italics">.</content>
<content stylecode="italics">4</content>)].<br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Pharmacology </content>
<content stylecode="italics">(</content>
<content stylecode="italics">12</content>
<content stylecode="italics">.</content>
<content stylecode="italics">3</content>)], which could increase or prolong both the therapeutic effects and adverse reactions, and may cause seizures and serotonin syndrome, and potentially fatal respiratory depression.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">If concomitant use is necessary, consider increasing the tramadol hydrochloride extended-release tablets dosage until stable drug effects are achieved. Follow patients for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider tramadol hydrochloride extended-release tablets dosage reduction and monitor for seizures and serotonin syndrome, and signs of sedation and respiratory depression.<br/>
<br/>Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of tramadol hydrochloride extended-release tablets and carbamazepine is not recommended.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Rifampin, carbamazepine, phenytoin<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Benzodiazepines </content>
<content stylecode="bold">and </content>
<content stylecode="bold">Other </content>
<content stylecode="bold">Central </content>
<content stylecode="bold">Nervous </content>
<content stylecode="bold">System </content>
<content stylecode="bold">(</content>
<content stylecode="bold">CNS</content>
<content stylecode="bold">) </content>
<content stylecode="bold">Depressants</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Warnings </content>
<content stylecode="italics">and </content>
<content stylecode="italics">Precautions </content>
<content stylecode="italics">(</content>
<content stylecode="italics">5</content>
<content stylecode="italics">.</content>
<content stylecode="italics">5</content>)].<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Serotonergic </content>
<content stylecode="bold">Drugs</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue tramadol hydrochloride extended-release tablets if serotonin syndrome is suspected.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Monoamine </content>
<content stylecode="bold">Oxidase </content>
<content stylecode="bold">Inhibitors </content>
<content stylecode="bold">(</content>
<content stylecode="bold">MAOIs</content>
<content stylecode="bold">)</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">MAOI interactions with opioids may manifest as serotonin syndrome <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Warnings </content>
<content stylecode="italics">and </content>
<content stylecode="italics">Precautions </content>
<content stylecode="italics">(</content>
<content stylecode="italics">5</content>
<content stylecode="italics">.</content>
<content stylecode="italics">6</content>
<content stylecode="italics">)] </content>or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">Warnings </content>
<content stylecode="italics">and </content>
<content stylecode="italics">Precautions </content>
<content stylecode="italics">(</content>
<content stylecode="italics">5</content>
<content stylecode="italics">.</content>
<content stylecode="italics">2</content>)].<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Do not use tramadol hydrochloride extended-release tablets in patients taking MAOIs or within 14 days of stopping such treatment.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">phenelzine, tranylcypromine, linezolid<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Mixed </content>
<content stylecode="bold">Agonist</content>
<content stylecode="bold">/</content>
<content stylecode="bold">Antagonist </content>
<content stylecode="bold">and </content>
<content stylecode="bold">Partial </content>
<content stylecode="bold">Agonist </content>
<content stylecode="bold">Opioid </content>
<content stylecode="bold">Analgesics</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">May reduce the analgesic effect of tramadol hydrochloride extended-release tablets and/or precipitate withdrawal symptoms.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Avoid concomitant use.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">butorphanol, nalbuphine, pentazocine, buprenorphine<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Muscle </content>
<content stylecode="bold">Relaxants</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of tramadol hydrochloride extended-release tablets and/or the muscle relaxant as necessary.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Diuretics</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Anticholinergic </content>
<content stylecode="bold">Drugs</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor patients for signs of urinary retention or reduced gastric motility when tramadol hydrochloride extended-release tablets are used concomitantly with anticholinergic drugs.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Digoxin</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Follow patients for signs of digoxin toxicity and adjust the dosage of digoxin as needed.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Warfarin</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Post-marketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.<br/>
</td>
</tr>
</tbody>
</table>